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hen it comes to brain disease, William Pardridge 
knows the numbers, and he’ll rattle them off at the 
drop of a hat. One in ﬁ  ve: the number of people 
with a disorder of the brain or central nervous system. Half 
a trillion dollars: what we’ll spend in the year 2020 to treat 
Alzheimer disease and stroke alone, and about what we now 
spend annually on national defense. And then there’s the 
number of good drugs available, after decades of research, to 
help brain cells survive in patients with those disorders: zero. 
Brain diseases by the dozens lack effective therapies, but it’s 
not for lack of trying, says Pardridge, a professor of medicine 
at the University of California, Los Angeles (United States): 
Pharmaceutical companies have failed to deliver effective new 
brain drugs, despite huge potential markets for Alzheimer 
disease, stroke, Parkinson disease, brain infections, and more. 
What’s more, “NIH is funding billions of dollars a year on 
molecular neuroscience research on the assumption that 
therapies for these diseases will be translated from the basic 
biological research,” but that assumption is proving to be 
false, he says. 
Those billions fund research that sheds light on the basic 
biology of brain diseases, which in many cases are still poorly 
understood. But the real problem in developing brain drugs, 
Pardridge maintains, is the blood-brain barrier, the super-
tight seal in the walls of the brain’s capillaries that protects 
the brain from brain-disrupting blood compounds like amino 
acids (which act as neurotransmitters), alkaloid toxins from 
plants, and other toxins. 
The same barrier, however, keeps out potentially beneﬁ  cial 
drugs. Only 2% of small-molecule compounds enter the 
brain on their own, even though they cross easily into other 
tissues. (Molecules are considered small if they’re less than 
400 daltons, roughly the size of sucrose.) No large molecules 
cross—no monoclonal antibodies, no gene therapies, no 
antisense and RNA interference compounds, no recombinant 
proteins. “We have come up with a number of potential 
agents that could beneﬁ  t humans,” says Thomas Jacobs, a 
program ofﬁ  cer at the US National Institute for Neurological 
Disorders and Stroke (NINDS) who directs both stroke 
and blood-brain barrier research, “but we run into a major 
roadblock when we try to deliver them to the nervous system.” 
And while biology is a major roadblock, the more 
important problem is that the ﬁ  eld of blood-brain barrier 
drug delivery has been neglected, underfunded, and 
underdeveloped, says Pardridge. “Not a single large 
pharmaceutical company in the world today has a blood-brain 
barrier drug-targeting program,” he says. And “not a single 
academic neuroscience program in the United States teaches 
blood-brain barrier drug delivery.” 
Unhappy with the progress, a few years ago Pardridge 
founded Armagen, a startup biotech company devoted to 
ﬁ  nding better ways to deliver drugs across the blood-brain 
barrier. Now, through the work of Pardridge’s team and a 
small group of other researchers, the ﬁ  eld of blood-brain 
barrier drug delivery is showing new signs of life.
Keeping the Brain Clean
The ﬁ  rst evidence for a blood-brain barrier arose in the late 
1800s, when the German immunologist Paul Ehrlich injected 
aniline dyes into a rat’s bloodstream in an effort to stain 
tissue. Every tissue in the rats stained crimson—except the 
brain and spinal cord. Later, his student Edwin Goldmann 
showed that dye injected into the cerebrospinal ﬂ  uid stained 
cells throughout the brain, but did not escape to stain 
peripheral tissues. Taken together, the two experiments 
showed that a tight seal existed between blood and brain. 
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“The walls of capillaries in peripheral 
tissues are like Swiss cheese, 
whereas the walls of capillaries 
in the brain are like cheddar cheese”  
—William Pardridge
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A network of capillaries supply brain cells with nutrients. Tight 
seals in their walls keep blood toxins—and many beneﬁ  cial 
drugs—out of the brain.PLoS Biology  |  www.plosbiology.org 1192
The nature of that seal did not become clear until the 
late 1960s, when electron micrographs of brain capillaries 
revealed that they differ from capillaries in the rest of the 
body. The endothelial cells that make up the walls of brain 
capillaries form tight junctions, preventing the passage of 
ﬂ  uid between individual cells. The cells also have fewer 
fenestrations, or tiny holes in their membranes, and they 
exhibit much less cellular drinking than endothelial cells in 
other tissues, reducing leakage. They also have nonselective 
pumps called P-glycoproteins to remove molecules that 
manage to sneak in. “The walls of capillaries in peripheral 
tissues are like Swiss cheese, whereas the walls of capillaries in 
the brain are like cheddar cheese,” Pardridge says. 
That tight seal “ensures the neuronal environment is 
crystal clean,” Pardridge says, which prevents the neural 
pandemonium that would ensue if blood compounds could 
easily enter brain tissue. But the tradeoff comes when drug 
researchers—and patients—want a drug to heal an ailing 
brain.
“To get drugs into the brain to treat disease, you’re going 
up against millions of years of development in man to 
keep out toxins and keep the brain healthy,” says medical 
pharmacologist Thomas Davis of the University of Arizona 
College of Medicine (United States). To deliver drugs to treat 
diseases of the central nervous system, “you try to fake the 
brain out,” Davis says.
Strategy Debates
Faking the brain out, however, is easier said than done, and 
according to Pardridge and other academic researchers, 
pharmaceutical companies have mostly botched the job. 
As Pardridge describes it, the pharmaceutical industry 
employs armies of medicinal chemists to develop hundreds 
of candidate drug compounds that they predict will cross 
the blood-brain barrier. Then they screen the promising 
compounds for activity in test-tube and cell-culture 
experiments, and then in rodents and other animals. Once 
inside the brain, such a drug might promote neuron growth, 
inhibit neuron degeneration, or stimulate repair. But often 
the companies ﬁ  nd out only during clinical trials that a drug 
fails to cross the human blood-brain barrier. 
That whole strategy is backwards, Pardridge maintains. 
Time after time, companies have learned too late that not 
enough of the drug enters the brain to beneﬁ  t patients. “A 
lot of companies have the attitude that we’ll cross the blood-
brain barrier problem when we get to it. That’s moronic,” he 
says. Other academic researchers put it a tad more gently, but 
basically agree. “Pharmaceutical companies wait until after 
drugs are developed to see if they get into the brain,” Davis 
says. “It’s a huge error.” 
Representatives of Eli Lilly and Company, Sanoﬁ  -Aventis, 
Merck, Amgen, and GlaxoSmithKline declined to speak to 
PLoS Biology for this story. But Steve Lederer, a spokesman 
for Pﬁ  zer, says that Pardridge’s depiction is a caricature of 
their process. Clinical trials are so expensive that “it would 
be insanity” to develop drugs and do clinical trials on them 
without knowing if they crossed the blood-brain barrier, he 
says. 
In addition to creating small molecules and screening them 
to see if they nurture or save neurons, Lederer says, Pﬁ  zer 
uses “very advanced computational modeling techniques” 
to predict, based on a molecule’s size and shape, whether 
it will cross the barrier, Lederer says. They choose only the 
compounds that computer modeling and animal experiments 
predict will work in the human brain. Then they do imaging 
studies on humans with tiny amounts of labeled drug to see 
whether it enters the brain. Finally, they use sophisticated 
biomarkers of activity during small phase I trials. In a trial of 
an experimental drug for Parkinson disease, the company 
used speech recognition technology to detect subtle changes 
on patient’s vocal cords, a sensitive measure of effectiveness. 
“We never progress to clinical trial unless we have a good 
understanding of what a drug is doing,” Lederer says.
Pardridge says that NIH and the academic neuroscience 
community share the blame for the failures of central nervous 
system drug development for focusing on basic molecular 
neuroscience research rather than important but less sexy 
translational research into the blood-brain barrier. NINDS’ 
Jacobs agrees that more could be done: “A Manhattan-type 
project on the blood-brain barrier would make tremendous 
strides, but the likelihood of that happening . . . there’s some 
difﬁ  culty.”
Nonetheless, the ﬁ  eld has recently picked up, with help 
from the NIH, Jacobs says. The NINDS, the National Institute 
of Mental Health, and the National Institute of Aging 
recently completed a three-year blood-brain barrier initiative 
speciﬁ  cally geared to coming up with new ways of delivering 
compounds to the brain. In October 2006, those three 
institutes and six others issued a new request for proposals 
with the same goal as part of NIH’s Neuroscience Blueprint 
Initiative. In the summer of 2006, academic blood-brain 
barrier researchers formed the International Brain Barriers 
Society (IBBS) to encourage “scientiﬁ  c and clinical research 
on the biological barriers in the central nervous system,” and 
in March of 2007, the organization hosted 125 leaders in the 
ﬁ  eld at a meeting in Stevenson, Washington, United States, to 
scope out the research challenges ahead.
Squeezing Through
Pardridge, for his part, has been scoping out those challenges 
for nearly four decades. His startup company, Armagen, has 
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Trojan horse molecules, such as monoclonal antibodies, can 
carry drugs (E) to brain cells.
“We have come up with a number of 
potential agents that could beneﬁ  t 
humans, but we run into a major 
roadblock when we try to deliver them 
to the nervous system.” —Tom Jacobs
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developed what Davis calls “probably the best technology 
in the world” to deliver drugs across the barrier. The 
technology, which has so far been tested only in animals, 
makes use of endothelial-cell transport proteins that normally 
move nutrients, hormones, or other peptides into the brain. 
Its design resembles the Trojan horse of ancient mythology: 
A monoclonal antibody looks familiar enough to convince 
the transporter to move it into brain tissue. The drug hitches 
a ride on the antibody into the brain tissue, then moves to 
diseased or damaged neurons to help them heal.
Last year, the company’s most advanced Trojan-horse drug, 
called AGT-120, prevented stroke-induced brain damage in 
rats. (Such a drug is desperately needed: no drug is approved 
by the US Food and Drug Administration (FDA) to nurture 
brain cells in the critical hours following a stroke.) AGT-120 
is a monoclonal antibody, an antibody speciﬁ  cally produced 
to bind a single part, or epitope, of a protein. AGT-120 
binds a capillary endothelial cell transporter that delivers a 
protein called transferrin into the brain, and it binds without 
interfering with the transporter’s activity. The payload is a 
peptide called brain-derived neurotrophic factor (BDNF), 
one of a large class of peptides called neurotrophins that 
nourish neurons. 
In a 2006 paper in Brain Research, Pardridge and research 
scientist Yun Zhang reported giving a rat-speciﬁ  c version 
of AGT-120 intravenously to animals that had an artiﬁ  cially 
induced ischemic stroke. AGT-120 reduced the volume of 
damaged cerebral tissue by 62% compared with intravenous 
BDNF alone, and it enabled the rats to balance on a spinning 
drum more than three times as long as rats treated only 
with BDNF, thereby proving that the Trojan horse strategy 
protected the animals from stroke-induced brain damage. 
The company will apply for FDA approval this year for a 
phase I clinical trial of AGT-120, and it’s developing seven 
other drugs for currently untreatable brain disorders, such as 
Alzheimer disease, Parkinson disease, mental retardation, and 
inborn errors of metabolism. 
Trojan horses can also deliver large molecules that would 
never stand a chance of crossing the barrier otherwise, 
including enzymes, monoclonal antibody drugs, RNA 
interference, and gene therapy (via Trojan horse–linked 
liposomes). 
Trojan-horse technologies are “very promising,” Jacobs says, 
but they “may not be a panacea, because they’re very speciﬁ  c 
and very specialized.” What’s more, says neuroscientist 
Maiken Nedergaard of the University of Rochester Medical 
Center (United States), the blood-brain barrier receptors 
exist elsewhere in the body, so “you get tremendous uptake in 
other organs.”
Neurosurgeons have developed alternative methods 
of disrupting the barrier, some of which have been used 
clinically. Some neurosurgeons have treated brain tumors by 
infusing small volumes of ﬂ  uid directly onto the affected parts 
of the brain. Early results were promising, but two recent 
phase III trials using the method, called convection-enhanced 
delivery, have failed. Edward Neuwelt, a neurosurgeon and 
neuroscientist at Oregon Health Sciences University and 
Portland Veteran’s Administration Hospital (United States), 
opens the blood-brain barrier in patients with brain tumors 
by snaking a catheter directly into the artery that supplies the 
affected part of the brain, then injecting a sugary solution, 
which sucks water out of endothelial cells. That shrinks 
them for up to half an hour and allows compounds as big as 
an antibody to squeeze through otherwise impervious tight 
junctions. 
In a 2001 study, Neuwelt reported that the osmotic 
disruption method enabled 42% of 74 patients with primary 
central nervous system lymphoma to live at least ﬁ  ve years 
longer than they would without treatment. Moreover, the 
method did not cause dementia, a common side effect of 
the chemotherapy and radiation that’s typically used to save 
such patients. Neuwelt and colleagues plan to present similar 
results from a 175-patient, multicenter trial at the American 
Society of Clinical Oncology meeting in June. The osmotic 
disruption method has drawbacks, however, admits Neuwelt. 
Only a few hospitals have neurosurgeons who have the special 
training needed. 
doi:10.1371/journal.pbio.0050169.g003
William Pardridge and the company he founded, Armagen, ferry 
drugs across the blood-brain barrier by attaching them to other 
molecules that act like a Trojan horse.
“A lot of companies have the attitude 
that we’ll cross the blood-brain barrier 
problem when we get to it. That’s 
moronic.” —William Pardridge
“It would be insanity to do that.” 
—Steve Lederer, spokesman for Pﬁ  zer
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Neuroscientists have developed several other targeting 
methods that show some promise in animals, Jacobs says. 
Some researchers deliver drugs via nasal inhalation, which 
deliver both large- and small-molecule drugs directly to the 
brain via the olfactory and trigeminal nerves, which relay 
sensory signals from the nose and mouth. Others have tested 
localized application of ultrasound to open up small areas 
of vasculature without causing tissue damage; Jacobs says 
the method “one day could help.” Neuroscientists have also 
used polymer nanoparticles to encapsulate and deliver a 
wide range of drugs, or they have loaded brain-penetrating 
macrophages with drug-linked nanoparticles. 
Still others, including many drug companies, argue that no 
targeting is really needed, because the blood-brain barrier 
opens naturally during many diseases. “But to rely on that 
as a way of getting drugs into the brain is not so rigorous,” 
Jacobs says. Indeed, despite all the research, “I don’t think 
there exists any way of selectively targeting the brain right 
now,” says Nedergaard, who cochaired the brain drug delivery 
section of the March International Brain Barriers Society 
conference.
That’s one reason neuroscientist Damir Janigro of 
Cleveland Clinic Foundation (United States) has spent years 
developing more and more realistic in vitro models of the 
human blood-brain barrier. The latest such model, called 
dynamic in vitro blood-brain barrier, consists of a porous 
hollow-ﬁ  ber tube that mimics a capillary wall. Endothelial 
cells line the inside wall of the tube; astrocytes, which regulate 
the blood brain barrier, cover the outside of the tube, and 
blood ﬂ  ow is mimicked by ﬂ  owing media that contains white 
blood cells. The model, which is being produced by a spin-
off company to sell to drug companies and researchers, can 
reproduce the properties of the healthy human blood-brain 
barrier as well as the altered blood-brain barrier of patients 
with multidrug-resistant epilepsy, according to a paper 
published online in February, 2007, in Epilepsia. It will be sold 
to drug companies to test drug permeability. “It’s incredibly 
important work,” says Arizona’s Davis.
Scientists have a long way to go to understand the basic 
biology of many brain diseases, and a great deal of basic 
neuroscience research is still needed, Jacobs says.  But 
experimental methods of crossing the blood-brain barrier 
form a crucial part of translating the research to the clinic. As 
such research picks up steam, the stakes are high. “It’s high 
risk, high gain,” says NIH’s Jacobs. “If we are successful, many, 
many people will beneﬁ  t.”  
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